Raute’s Q3 figures were encouraging, and even if FY’26 EBITDA would decline more than we estimate th...
With the admission to the London Stock Exchange Main Market, at Friday, 31st October, and the prospe...
Redeye provides an initial comment on Tradedoubler’s Q3 2025 report.
* 38% y-o-y organic sales growth in Q3'25e * EBIT forecasts cut by 4.
* Adj. EBITA EUR 9.1m, above ABGSCe 7.0m and up y-o-y * We raise our adj.
* Organic momentum improved in all segments * A recovery in Swedish housing could drive 18% EBITA gr...
* Increasing activity in the letting market * Net financials miss in Q3 drives negative revisions * ...
* Q3 report Friday, 7 April at 08:30 CET * '25e-'27e adj.
Redeye updates on Gentoo Media ahead of Q3-results (due 18 November) where we expect limited topline...
Redeye reviews SynAct Pharma's Q3 report. The ADVANCE study is progressing and on track to enrol all...
Continued gross margin expansion, but the market remains tough We take a more cautious view on the r...
Redeye provides a research update following the Q3 report published by OncoZenge earlier today.
Elon AB säger upp kedjeavtalet med sin största handlarkedja, Kökscentrum Södra AB och Belab Elbutik ...
Redeye returns with a new note after gaining more insights from Monday’s webcast.
Finnair’s Q3 revenue was lower than estimated as ticket prices developed softer than we expected.
Despite the profit warning released ahead of the Q3 report, there were also positives in the report ...
Solteq’s Q3 results were disappointing. Despite the weak quarter, guidance was reiterated, indicatin...
YIT's net sales in Q3 amounted to EUR 402m (Evli/cons.
Raute recently issued another positive profit warning, according to which FY’25 revenue will be slig...
Redeye comments on CTEK’s Q3 report, which showed weaker growth than expected, but this was compensa...
